Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Articles
BioCentury
|
Apr 30, 2012
Company News
Aspen Pharmaceutical Holdings Ltd., GlaxoSmithKline sales and marketing update
...million) in cash. Business: Generics GSK divested non-core consumer healthcare OTC products in Europe to
Omega Pharma N.V.
...
Read More
BioCentury
|
Mar 19, 2012
Company News
GlaxoSmithKline, Omega Pharma deal
...million ($668 million) in cash (see BioCentury, Jan. 2). GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Omega Pharma N.V.
...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
Apr 30, 2012
Company News
Aspen Pharmaceutical Holdings Ltd., GlaxoSmithKline sales and marketing update
...million) in cash. Business: Generics GSK divested non-core consumer healthcare OTC products in Europe to
Omega Pharma N.V.
...
Read More
BioCentury
|
Mar 19, 2012
Company News
GlaxoSmithKline, Omega Pharma deal
...million ($668 million) in cash (see BioCentury, Jan. 2). GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Omega Pharma N.V.
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page